Abstract
Arsenic trioxide (As2O2) has been used medicinally for thousands of years. Its therapeutic use in leukaemia was described a century ago. Recent rekindling in the interest of As2O3 is due to its high efficacy in acute promyelocytic leukaemia (APL). As2O3 has also been tested clinically in other blood and solid cancers. Most studies have used intravenous As2O3, although an oral As2O3 is equally efficacious. Side effects of As2O3 are usually minor, including skin reactions, gastrointestinal upset, and hepatitis. These respond to symptomatic treatment or temporary drug cessation, and do not compromise subsequent treatment with As2O3. During induction therapy in APL, a leucocytosis may occasionally occur, which can be associated with fluid accumulation and pulmonary infiltration. The condition is similar to the APL differentiation syndrome during treatment with all-trans retinoic acid, and responds to cytoreductive treatment and corticosteroids. Intravenous As2O3 treatment leads to QT prolongation. In the presence of underlying cardiopulmonary diseases or electrolyte disturbances, particularly hypokalaemia and hypomagnesaemia, serious arrhythmias may develop, with torsades du pointes reported in 1% of cases. This may be related to a dose-dependent arsenic-mediated inhibition of potassium ion channels that compromises cardiac repolarization. Because of slow intestinal absorption, oral-As2O3 gives a lower plasma arsenic concentration, which is associated with lesser QT prolongation and hence a more favorable cardiac safety profile. As2O3 does not appear to enter the central nervous system. However, if the blood brain barrier is breached, elemental arsenic may enter the cerebrospinal fluid. As2O3 is predominantly excreted in the kidneys, and dose adjustment is required when renal function is impaired.
Similar content being viewed by others
Article PDF
References
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328–35.
Mari F, Bertol E, Fineschi V, Karch SB . Channelling the Emperor: what really killed Napoleon? J R Soc Med 2004; 97: 397–9.
Kwong YL, Todd D . Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997; 89: 3487–8.
Chowdhury UK, Biswas BK, Chowdhury TR, Samanta G, Mandal BK, Basu GC, et al. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect 2000; 108: 393–7.
Mazumder DN, Das Gupta J, Santra A, Pal A, Ghose A, Sarkar S . Chronic arsenic toxicity in west Bengal—the worst calamity in the world. J Indian Med Assoc 1998; 18: 96: 4–7.
Douer D, Tallman MS . Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396–410.
Wang ZY . Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology (Am Soc Hematol Educ Program) 2003: 1–13.
Ratnaike RN . Acute and chronic arsenic toxicity. Postgrad Med J 2003; 79: 391–6.
Schoolmeester WL, White DR . Arsenic poisoning. South Med J 1980; 73: 198–208.
Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL . Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective. Cancer Chemother Pharmacol 2005; 55: 170–8.
Annonymous Toxic summary for arsenic. Risk Assessment Information System database 1992; Cited Nov 2007. Available from URL: http://risk.lsd.ornl.gov/tox/profiles/arseni_c.shtml.
Santra A, Das Gupta J, De BK, Roy B, Guha Mazumder DN . Hepatic manifestations in chronic arsenic toxicity. Indian J Gastroenterol 1999; 18: 152–5.
Datta D V, Narang AP, Arya P, Sahni MM, Banerjee CK, Walia BN, et al. Indian childhood cirrhosis. Lancet 1979; 2: 641.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–24.
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–60.
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–8.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–60.
Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J . Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003; 97: 2218–24.
Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326–34.
Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002; 58: 521–6.
Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003; 102: 407–8.
Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfde for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136–43.
Borad MJ, Swift R, Berenson JR . Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005; 19: 154–6.
Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658–68.
Wang ZY . Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 2001; 48: S72–6.
Guha Mazumder DN . Arsenic and liver disease. J Indian Med Assoc 2001; 99: 311–20.
Liu J, Zheng B, Aposhian H V, Zhou Y, Chen ML, Zhang A, et al. Chronic arsenic poisoning from burning high-arsenic-containing coal in Guizhou, China. Environ Health Perspect 2002; 110: 119–22.
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742–9.
Lu JN, Chen CJ . Prevalence of hepatitis B surface antigen carrier status among residents in the endemic area of chronic arsenicism in Taiwan. Anticancer Res 1991; 11: 229–33.
Hughes GS Jr, Davis L . Variegate porphyria and heavy metal poisoning from ingestion of “moonshine”. South Med J 1983; 76: 1027–9.
Tsai SM, Wang TN, Ko YC . Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health 1999; 54: 186–93.
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617–22.
Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103: 1092–5.
Tanvetyanon T, Nand S . Herpes zoster during treatment with arsenic trioxide. Ann Hematol 2004; 83: 198–200.
Satterlee HS . The arsenic-poisoning epidemic of 1900. Its relation to lung cancer in 1960 - an exercise in retrospective epidemiology. N Engl J Med 1960; 263: 676–84.
Au W Y, Kwong YL . Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol 2005; 53: 890–2.
Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004; 28: 909–19.
Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004; 28: 791–803.
Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, et al. Phase II trial of arsenic trioxide and alpha interferon in patient with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5: 130–4.
Barbey JT, Soignet S . Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2001; 135: 842–3.
Barbey JT, Pezzullo JC, Soignet SL . Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003; 21: 3609–15.
Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514–6.
Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266–71.
Chiang CE, Luk HN, Wang TM, Ding PY . Prolongation of cardiac repolarization by arsenic trioxide. Blood 2002; 100: 2249–52.
Wu MH, Lin CJ, Chen CL, Su MJ, Sun SS, Cheng AL . Direct cardiac effects of Assb>2O3 in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration. Toxicol Appl Pharmacol 2003; 189: 214–20.
Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66: 33–44.
Drolet B, Simard C, Roden DM . Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004; 109: 26–9.
Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications on long-term cardiac safety. Blood 2006; 108: 103–6.
Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R, Wiernik PH . Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 2004; 124: 610–7.
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133: 881–5.
Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18: 2620–5.
Roberts TF, Sprague K, Schenkein D, Miller KB, Relias V . Hyperleu-kocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood 2000; 96: 4000–1.
Au WY, Ma SK, Ooi C, Liang R, Kwong YL . Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission. J Clin Oncol 2000; 18: 3435–7.
Yip SF, Yeung YM, Tsui EY . Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency. Blood 2002; 99: 3481–2.
Rodriguez VM, Carrizales L, Mendoza MS, Fajardo OR, Giordano M . Effects of sodium arsenite exposure on development and behavior in the rat. Neurotoxicol Teratol 2002; 24: 743–50.
Au W Y, Tam S, Fong BM, Kwong YL . Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 2006; 107: 3012–3.
Au W Y, Tam S, Kwong YL . Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. Leuk Res 2007 Jul 25; [Epub ahead of print].
Au WY, Chim CS, Lie AK, Liang R, Kwong YL . Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117: 130–2.
Galm O, Fabry U, Osieka R . Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. Leukemia 2000; 14: 343–4.
Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV . Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001; 108: 1541–7.
Axelson O, Dahlgren E, Jansson CD, Rehnlund SO . Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br J Ind Med 1978; 35: 8–15.
Luchtrath H . The consequences of chronic arsenic poisoning among Moselle wine growers. Pathoanatomical investigations of postmortem examinations performed between 1960 and 1977. J Cancer Res Clin Oncol 1983; 105: 173–82.
Au WY, Kumana CR, Lam CW, Cheng VC, Shek TW, Chan EY, et al. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia. Leuk Res 2007; 31: 105–8.
Fascineli ML, Hunter ES, 3rd, De Grava Kempinas W. Fetotoxicity caused by the interaction between zinc and arsenic in mice. Teratog Carcinog Mutagen 2002; 22: 315–27.
Au WY, Cheung GT, Yuen TW, Kumana CR, Kwong YL . Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med 2005; 165: 1067–8.
Fenaux P, Chevret S, de Botton S . Treatment of older adults with acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 495–501.
Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001; 15: 735–41.
Au WY, Lie AK, Chim CS, Liang R, Ma SK, Chan CH, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003; 14: 752–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Ruby and Minoo N Master Charity Foundation.
Rights and permissions
About this article
Cite this article
Au, WY., Kwong, YL. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 29, 296–304 (2008). https://doi.org/10.1111/j.1745-7254.2008.00771.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00771.x
Keywords
This article is cited by
-
Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date
Archives of Pharmacal Research (2024)
-
Urolithin A attenuates arsenic-induced gut barrier dysfunction
Archives of Toxicology (2022)
-
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
Experimental Hematology & Oncology (2021)
-
Targeted therapy of human leukemia xenografts in immunodeficient zebrafish
Scientific Reports (2021)
-
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma
Leukemia (2017)